Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital)

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameAnti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital)
Drug Alias NameCD19 CAR-T (新桥医院)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > LNP +[4] 
Mechanisms of ActionAnti-CD19T lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe Second Affiliated Hospital of Army Medical University
China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of Army Medical University
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A